Radioimmunotherapy With 131I-L19SIP in Patients With Cancer

NCT01242943 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped With the determination of the RD and a well established understanding of the safety and tolerability profile, the main endpoints of the study have been met.

Conditions

Interventions

Sponsor

Philogen S.p.A.